Mallinckrodt and Endo announce combined leadership team; GxSI spin-off named Par Health with CEO Stephen Welch

Keenova Therapeutics plc

Senior leadership team for merged company includes execs from both firms (e.g., Lisa French, Mark Bradley, Mark Tyndall).
Mark Bradley (Endo CFO) to serve as Chief Integration Officer; CFO role is open and recruiting.
Generics & sterile injectables spin-off will be named Par Health; Stephen Welch (Mallinckrodt Specialty Generics head) to lead as CEO upon spin-off.
Merger remains on track to close in H2 2025, subject to shareholder approvals and customary conditions.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.